Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A novel test shows promise for finding cervical adenocarcinoma, which is difficult to find.

2.

Researchers publish action plan to address appendiceal cancer enigmas

3.

AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns

4.

Underprescribed for Alcohol Use Disorder is pharmacotherapy.

5.

Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot